Cancer Research

Pancreatic cancer
#Oncology #Panavance Therapeutics #Pancreatic cancer #Phase I trial

Interim data reveals potential of new pancreatic cancer drug

Misetionamide (GP-2250) in combination with gemcitabine has demonstrated a good safety profile and potential therapeutic benefit in the treatment of pancreatic adenocarcinoma. Panavance Therapeutics revealed the interim data from its Phase I clinical study at the 2024 Visceral Medicine Congress in Leipzig, Germany. The… Read More

#Cancer Research #News

Therapeutic antibodies
#Bispecific Antibodies #Interview #Lymphoma #Oncology

Q&A: Targeting difficult to treat lymphomas with a bispecific antibody

DDW Editor Reece Armstrong speaks to Tahi Ahmadi, MD, PhD, Executive Vice President & Chief Medical Officer, Head of Experimental Medicines, Genmab & Jacqueline Nielsen, PhD, Therapeutic Head, Hematology, AbbVie, about the recommendation and the development of epcoritamab. Earlier this year, the European Medicines Agenecy’s (EMA) Committee for Medicinal Products… Read More

#Cancer Research #Exclusive Content

Cancer cell
#Cancer drug targets #Drug resistance #EMBL European Bioinformatics Institute #Gene mutation #Genetics / genomics #Oncology #Wellcome Sanger Institute

Drug resistance study boosts discovery of next-generation cancer drugs

New research has detailed each type of cancer mutation that causes drug resistance, helping to uncover targets for drug development and identify potential effective second-line therapies. In a new large-scale study, researchers from the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), Open Targets, and collaborators… Read More

#Cancer Research #News #Trending News

Cell therapy
#Cell therapy #Immunotherapy #Oncology #Solid tumours #T cell activation #Turning Science into Business

Are TILs the next big thing in cancer treatment?

DDW’s Megan Thomas speaks with Dr Chantale Bernatchez, Director of Cell Therapy Process Development at CTMC, about tumour infiltrating lymphocyte (TIL) therapy and what’s on the horizon for this new class of cell therapy. TIL therapy is a form of cancer immunotherapy. It’s an autologous cell therapy, meaning cells are… Read More

#Cancer Research #Exclusive Content

Cancer cells
#Aprea Therapeutics #Cancer research #Clinical trials #Solid tumours #Tumour biology

Cancer therapy innovation to overcome traditional limitations 

DDW’s Megan Thomas interviews Dr Oren Gilad, President and CEO of Aprea Therapeutics, about the company’s targeted therapeutics that overcome the traditional issues associated with chemotherapy such as toxicity and tumour resistance.  MT: Can you provide an overview of Aprea Therapeutics’ approach to developing new cancer therapies… Read More

#Cancer Research #Exclusive Content

Blood samples in lab
#Drug discovery #Indivumed Therapeutics #Molecular Biology #Oncology #Sample preparation

Fast changes within tumour samples could mislead researchers

Significant changes in the molecular characteristics of tumour samples occur within as little as 10 minutes after surgical removal, a new study led by Indivumed Therapeutics has revealed. The findings underline the importance of rapid snap freezing of tissue samples to reliably capture cancer biology and… Read More

#Cancer Research #News

Cancer immunotherapy
#Immunotherapy #Oncology #The Francis Crick Institute #The Royal Marsden NHS Foundation Trust #UK

UK-wide programme to boost success of immunotherapy

A team of UK universities, hospitals and industry, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust, have launched a new platform to understand immunotherapy response and side effects in cancer. The programme will be funded by £9 ($11.7) million from the… Read More

#Cancer Research #News

Bladder cancer
#Bladder cancer #Drug repurposing #Mouse models #Oncology #Preclinical investigations

Diabetes and cancer drug combo shrinks bladder tumours by 91%

A new study in mice by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) in New York has identified a promising drug combination for the treatment of muscle-invasive bladder cancer. Rosiglitazone plus trametinib worked synergistically to not only induce tumour cell death, but also shift… Read More

#Cancer Research #Editor's Choice #News

CAR T-cells attacking a cancer cell
#CAR-T #Haematology #Myeloma #Oncology #Phase I trial #Poseida Therapeutics #Roche

Patients show 91% response to allogeneic CAR-T therapy

Investigators saw a 91% overall response rate (ORR) in patients with relapsed/refractory multiple myeloma (RRMM) following treatment with allogeneic CAR-T therapy P-BCMA-ALLO1 and lymphodepletion. The interim data from an ongoing Phase I trial in patients who have previously received three or more prior lines of therapy… Read More

#Cancer Research #News

#Brain cancer #Cancer Research UK #Funding #Oncology #Paediatrics

£3m boost to paediatric brain cancer research

Experts from Cancer Research UK Children’s Brain Tumour Centre of Excellence in Cambridge, UK are set to share around £3.2 ($4.2) million to find and test better and less toxic ways to treat children’s brain tumours. The funding announcement comes during Childhood Cancer Awareness Month. Read More

#Cancer Research #News